S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:VSTM

Verastem (VSTM) Stock Price, News & Analysis

$11.82
+0.23 (+1.98%)
(As of 03/27/2024 ET)
Today's Range
$11.54
$12.26
50-Day Range
$10.39
$14.07
52-Week Range
$4.20
$15.18
Volume
168,710 shs
Average Volume
170,589 shs
Market Capitalization
$299.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.79

Verastem MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
143.5% Upside
$28.79 Price Target
Short Interest
Bearish
3.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.15mentions of Verastem in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$107,388 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.31) to ($2.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.97 out of 5 stars

Medical Sector

720th out of 939 stocks

Pharmaceutical Preparations Industry

333rd out of 436 stocks

VSTM stock logo

About Verastem Stock (NASDAQ:VSTM)

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

VSTM Stock Price History

VSTM Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Verastem's (VSTM) Buy Rating Reiterated at HC Wainwright
VSTM Apr 2024 11.000 call
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
VSTM Apr 2024 14.000 call
Recap: Verastem Q4 Earnings
VSTM Stock Earnings: Verastem Misses EPS for Q4 2023
VSTM Mar 2024 2.000 put
Verastem Stock (NASDAQ:VSTM), Short Interest Report
See More Headlines
Receive VSTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/27/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VSTM
CUSIP
92337C10
Fax
N/A
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.79
High Stock Price Target
$36.00
Low Stock Price Target
$17.50
Potential Upside/Downside
+143.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-87,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.60 million
Book Value
$2.27 per share

Miscellaneous

Free Float
24,561,000
Market Cap
$299.05 million
Optionable
Optionable
Beta
0.49
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Daniel W. Paterson (Age 63)
    President, CEO & Director
    Comp: $697.98k
  • Mr. Daniel Calkins (Age 36)
    CFO, Head of Investor Relations, Principal Accounting & Financial Officer
    Comp: $1.42M
  • Mr. Richard H. Aldrich M.B.A. (Age 70)
    Founder and Consultant
    Comp: $38.39k
  • Dr. Robert A. Weinberg Ph.D.
    Co-Founder & Chair of Scientific Advisory Board
  • Dr. Piyush B. Gupta Ph.D.
    Co-Founder
  • Dr. Michelle Dipp M.D. (Age 48)
    Ph.D., Co-Founder
  • Mr. Robert Pintar M.B.A.
    Senior Vice President of Technical Operations
  • Dr. Jonathan Pachter Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $238.18k
  • Mr. Nate Sanburn
    Senior Vice President of Corporate Development & External Engagement
  • Dr. Hagop Youssoufian M.D. (Age 67)
    M.Sc., Ph.D., Head of Medical Strategy

VSTM Stock Analysis - Frequently Asked Questions

Should I buy or sell Verastem stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VSTM shares.
View VSTM analyst ratings
or view top-rated stocks.

What is Verastem's stock price target for 2024?

7 Wall Street research analysts have issued 1 year price objectives for Verastem's shares. Their VSTM share price targets range from $17.50 to $36.00. On average, they predict the company's share price to reach $28.79 in the next year. This suggests a possible upside of 143.5% from the stock's current price.
View analysts price targets for VSTM
or view top-rated stocks among Wall Street analysts.

How have VSTM shares performed in 2024?

Verastem's stock was trading at $8.14 on January 1st, 2024. Since then, VSTM shares have increased by 45.2% and is now trading at $11.82.
View the best growth stocks for 2024 here
.

When is Verastem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VSTM earnings forecast
.

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) released its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.96) by $0.60.

When did Verastem's stock split?

Shares of Verastem reverse split on the morning of Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Robert Forrester's approval rating as Verastem's CEO?

11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).

Who are Verastem's major shareholders?

Verastem's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Royal Bank of Canada (0.22%), Dimensional Fund Advisors LP (0.16%), Goldman Sachs Group Inc. (0.09%), Goldman Sachs Group Inc. (0.09%), Stifel Financial Corp (0.07%) and International Assets Investment Management LLC (0.04%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins and Robert E Gagnon.
View institutional ownership trends
.

How do I buy shares of Verastem?

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VSTM) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners